Maxim Yu. Rykov
Tver State Medical University, Russia
Title: Cell technologies in the treatment of patients with postcovid syndrome
Biography
Biography: Maxim Yu. Rykov
Abstract
The inclusion of stem cells (SC) in rehabilitation programs for patients with various injuries and diseases of the central nervous system is a new, promising direction of research. Possible mechanisms of therapy for spinal cord injury based on the use of adult-type stem cells from the bone marrow, including CD34 +, include many aspects. On the background of SC transplantation, damaged nerve cells and surrounding tissues, including neurons and glial cells, can be restored, which helps to ensure the integrity of the nerve conduction pathway and, thus, restore nerve function. SA therapy can suppress genes involved in inflammation and apoptosis, as well as activate genes with neuroprotective action, thereby protecting spinal neurons from secondary damage. The introduction of autoCD34 + SC will be performed intrathecally by spinal (lumbar) puncture performed in the L2-L3 gap, under local anesthesia with 1% lidocaine solution. The dose of autoCD34 + SC is determined by the content of CD34 + cells and is not less than 1x106 CD34 + cells per 1 injection. Autologous hematopoietic stem cells (HSC) obtained from the patient himself do not cause immunological conflicts, and, accordingly, do not require immunosuppressive therapy, unlike donor (allogeneic) and xenogenic cells. Thus, the patient does not experience disturbances in the natural mechanisms of anti-infectious and antitumor control. At the same time, autologous HSCs are relatively easy to obtain and cultivate if necessary, and when using this type of cells, doctors do not face ethical and legislative challenges.